Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Diabetes Care. 2024 Oct 1;47(10):1834-1837. doi: 10.2337/dc24-1082.
To determine patient characteristics and dose titration patterns of real-world semaglutide (Wegovy) users.
We used a population-based cohort study including Danish adults who filled semaglutide prescriptions from 12 December 2022 to 31 December 2023. Outcomes were patient characteristics, prescriber type, and dose titration patterns.
We identified 110,748 individuals (median age 49 years; 70% female) filling 773,708 prescriptions for semaglutide. General practitioners initiated treatment in 86%. Common comorbidities included hypertension (30%), dyslipidemia (17%), and arthrosis (17%). Only 13% reached the maximum dose of 2.4 mg by their fifth prescription, while 5.7% stopped after the first prescription. Few users (10%) followed recommended dose increases every 4 weeks. Overall, 25% filled at least one prescription of 2.4 mg, while 33-48% continued with the 1.0-mg dosage from the fourth prescription onward.
Real-world semaglutide users generally resembled trial participants, but few follow the dose titration schemes tested in premarket clinical trials.
确定真实世界中司美格鲁肽（Wegovy）使用者的患者特征和剂量调整模式。
我们使用了一项基于人群的队列研究，纳入了自 2022 年 12 月 12 日至 2023 年 12 月 31 日期间在丹麦开具司美格鲁肽处方的成年人。结局指标为患者特征、处方医师类型和剂量调整模式。
我们共确定了 110748 名（中位年龄 49 岁；70%为女性）患者，共开具了 773708 张司美格鲁肽处方。86%的处方由全科医生开具。常见合并症包括高血压（30%）、血脂异常（17%）和骨关节炎（17%）。仅有 13%的患者在第 5 次处方时达到了 2.4mg 的最大剂量，而 5.7%的患者在第 1 次处方后就停止了治疗。只有少数（10%）患者遵循了每 4 周增加一次剂量的建议。总体而言，25%的患者至少开具了 1 张 2.4mg 的处方，而 33%-48%的患者在第 4 次处方后继续使用 1.0mg 的剂量。
真实世界中的司美格鲁肽使用者通常与临床试验中的参与者相似，但很少遵循上市前临床试验中测试的剂量调整方案。
